JAGX Valuation

Jaguar Health Inc

Add to Watchlist

Advanced Chart

2.070

+0.04(1.970%)1D

Overview
Forecast
Valuation
Earnings

JAGX Relative Valuation

JAGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAGX is overvalued; if below, it's undervalued.

Historical Valuation

Jaguar Health Inc (JAGX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.19. The fair price of Jaguar Health Inc (JAGX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.03

Fair

-0.16

Trailing

Forward

-3.24

EV/EBITDA

Jaguar Health Inc. (JAGX) has a current EV/EBITDA of -3.24. The 5-year average EV/EBITDA is 3.10. The thresholds are as follows: Strongly Undervalued below -24.58, Undervalued between -24.58 and -10.74, Fairly Valued between 16.95 and -10.74, Overvalued between 16.95 and 30.79, and Strongly Overvalued above 30.79. The current Forward EV/EBITDA of -3.24 falls within the Historic Trend Line -Fairly Valued range.

-1.33

EV/EBIT

Jaguar Health Inc. (JAGX) has a current EV/EBIT of -1.33. The 5-year average EV/EBIT is -2.47. The thresholds are as follows: Strongly Undervalued below -7.48, Undervalued between -7.48 and -4.97, Fairly Valued between 0.03 and -4.97, Overvalued between 0.03 and 2.54, and Strongly Overvalued above 2.54. The current Forward EV/EBIT of -1.33 falls within the Historic Trend Line -Fairly Valued range.

0.26

Jaguar Health Inc. (JAGX) has a current PS of 0.26. The 5-year average PS is 3.54. The thresholds are as follows: Strongly Undervalued below -8.92, Undervalued between -8.92 and -2.69, Fairly Valued between 9.77 and -2.69, Overvalued between 9.77 and 16.00, and Strongly Overvalued above 16.00. The current Forward PS of 0.26 falls within the Historic Trend Line -Fairly Valued range.

-0.24

P/OCF

Jaguar Health Inc. (JAGX) has a current P/OCF of -0.24. The 5-year average P/OCF is -1.63. The thresholds are as follows: Strongly Undervalued below -6.42, Undervalued between -6.42 and -4.02, Fairly Valued between 0.77 and -4.02, Overvalued between 0.77 and 3.16, and Strongly Overvalued above 3.16. The current Forward P/OCF of -0.24 falls within the Historic Trend Line -Fairly Valued range.

-0.38

P/FCF

Jaguar Health Inc. (JAGX) has a current P/FCF of -0.38. The 5-year average P/FCF is 3.96. The thresholds are as follows: Strongly Undervalued below -31.24, Undervalued between -31.24 and -13.64, Fairly Valued between 21.57 and -13.64, Overvalued between 21.57 and 39.17, and Strongly Overvalued above 39.17. The current Forward P/FCF of -0.38 falls within the Historic Trend Line -Fairly Valued range.

Jaguar Health Inc (JAGX) has a current Price-to-Book (P/B) ratio of 0.56. Compared to its 3-year average P/B ratio of 1.08 , the current P/B ratio is approximately -47.93% higher. Relative to its 5-year average P/B ratio of 3.43, the current P/B ratio is about -83.53% higher. Jaguar Health Inc (JAGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -419.24%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -275.98% , the current FCF yield is about -100.00% lower.

0.56

P/B

Median3y

1.08

Median5y

3.43

-684.17

FCF Yield

Median3y

-419.24

Median5y

-275.98

Competitors Valuation Multiple

The average P/S ratio for JAGX's competitors is 0.00, providing a benchmark for relative valuation. Jaguar Health Inc Corp (JAGX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 9.48%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Biodexa Pharmaceuticals PLC

Theriva Biologics Inc

Loss

3.88M

Performance Decomposition

Market capitalization of JAGX decreased by 93.66% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.72M to 2.98M.

The secondary factor is the Margin Expansion, contributed 0.18%to the performance.

Overall, the performance of JAGX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

9.48%

2.72M → 2.98M

Revenue Growth

0.18%

-353.84 → -354.48

Margin Expansion

-103.32%

2.30 → -0.08

P/E Change

-93.66%